PrimeC Shows Significant Long-term Functional Benefit and Reduced Mortality in ALS: Insights from the PARADIGM Trial
The Phase 2b PARADIGM trial reveals that PrimeC, a novel oral combination therapy, is safe and significantly slows functional decline and reduces the risk of death or hospitalization in ALS patients over 18 months.